|

Recombinant Granulocyte Colony-Stimulating Factor Clinical Trials

5 actively recruiting trials across 3 locations

Also known as: 143011-72-7, Recombinant Colony-Stimulating Factor 3, rhG-CSF

Seattle, Washington3 trials

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Duarte, California1 trial

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

City of Hope Medical Center

Phase 2

Atlanta, Georgia1 trial

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Emory University Hospital/Winship Cancer Institute

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.